Stacy Masucci’s Post

Always great to see positive progress in PGx being reinforced as standard of care. Pharmacogenomics: A road ahead for precision medicine in psychiatry "Genomics offers two main prospects for psychiatry. First, it provides a potentially unbiased route to understanding pathogenesis and pathophysiology. Second, it can potentially provide novel predictive tests for research and clinical practice (Owen and O’Donovan, 2020). These two elements come together in pharmacogenomics, which will be central to delivering precision medicine and within it, precision psychiatry. Pharmacogenomics offers a way to improve our understanding of the metabolism, safety, and efficacy of psychiatric drugs, while potentially contributing to their development or repurposing (Schuck and Grillo, 2016; Yin and Vandell, 2019). It will also allow us to delineate groups of individuals who could benefit from particular therapeutic strategies (Rees and Owen, 2020)." #pgx #pharmacogenomics #pharmacists #psychiatry RESOLVE MOLECULAR DIAGNOSTICS LLC https://lnkd.in/e6CPmZHb

Do you know what a Learning Health System is and why it matters to the future of innovative mental health treatments? This article spells it out.

I am excited to share this new study from Translational Psychiatry that shows the potential of a novel brain stimulation technique called Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) in reducing suicidal ideation in patients with major depressive disorder (MDD). This is a groundbreaking discovery that could pave the way for more effective and rapid interventions for patients with MDD who are at high risk of suicide. I encourage you to read the full article here and learn more about this innovative and promising therapy.

Precision psychiatry is about to takeoff, but is our healthcare system ready? In a recent article published in Fierce Pharma, L. Alison McInnes MD, MS and Jimmy Qian explore the exciting advancements in psychiatry and the challenges we face in implementing them. Let's dive in: Progress: • Characterization of neural circuitry for specific symptoms • Development of novel mechanisms of action (MOAs) for targeted therapies • Potential treatments for previously untreatable conditions Challenges: • Lack of consensus on measuring transdiagnostic symptoms • Increased demands on clinicians to navigate complex treatment pathways • Difficulty in diagnosing and measuring newly treatable conditions The solution? A Learning Health System that bridges research and clinical care by: 1️⃣ Aligning stakeholders across the healthcare spectrum 2️⃣ Deploying precision measurements at the point of care 3️⃣ Generating well-characterized patient cohorts for ongoing research As we move towards a causality-based nosology in psychiatry, collaboration is key. Husseini Manji, M.D., F.R.C.P.C.., Osmind Strategic Advisor emphasizes, "We must work collaboratively across sectors to create a seamless integration of precision diagnostics and targeted therapeutics into everyday practice and real-world outcomes." Ready to bridge the gap? Read the full article to learn how to ensure that breakthrough research translates into improved patient care. https://lnkd.in/gUd8UTT3 #PrecisionMedicine #PsychiatryInnovation #HealthcareTechnology

Join me in celebrating 100 years of EEG, please reshare! On July 6th, 1924 Hans Berger recorded the first EEG on a human, only published in 1929. This invention of the EEG has resulted in many clinical applications ranging from diagnosing epilepsy and sleep disorders to Brain Machine Interfaces (BMI/BCI), neurofeedback and EEG as the first clinically actionable biomarker in precision and stratified psychiatry. What's your favorite application of EEG? See the full series 'Pioneers of the EEG' here: https://lnkd.in/giNVN5q also in Spanish.

According to a recent analysis published in Translational Psychiatry, ketamine has been the most extensively researched drug for depression in clinical trials worldwide over the last 30 years. This review analyzed all clinical trials registered globally between 1990 and 2020, and found 137 trials that studied ketamine for MDD, half again as much as the next-most studied drug for depression. As this study helps illustrate, ketamine treatment for depression is well established in scientific research - with over 2,000 scientific papers referencing ketamine and depression on PubMed alone. This wealth of literature informs Ember's care model and enables us to safely and effectively serve our patients. To read the study, please use the link below. If you're interested in exploring care with Ember, or referring a patient, please email us at intake@emberhealth.co. Link to Translational Psychiatry study: https://lnkd.in/eSn5b2Dz Link to PubMed: https://lnkd.in/eQYGxNqC

This atlas is the first fully visual reference to cover psychiatry broadly, appealing to psychiatric as well as non-psychiatric clinicians and trainees who need an easy-to-use visual resource with holistic approach to patient care.  The first atlas to cover psychiatry broadly Richly illustrated with tables, imaging scans, for visual learners, busy clinicians, and ESL students Written by expert clinicians and academicians in psychiatry and medical education Keywords Neuroimaging diagnostics and testing Psychiatric neurobiology Neurocognitive disorders Somatic symptoms Visual approach to psychiatry

🌟 Pioneering Advances in Psychiatry: AbbVie and Gilgamesh Pharmaceuticals Forge $2 Billion Neuroplastogen Partnership 🧠 AbbVie and Gilgamesh Pharmaceuticals have announced a landmark deal worth up to $2.01 billion to develop next-gen therapies for psychiatric disorders. This collaboration merges AbbVie’s expertise in psychiatry with Gilgamesh’s cutting-edge research on neuroplastogens, targeting mood and anxiety disorders with fewer side effects. Jonathon Sedgwick, AbbVie’s VP of Discovery Research, states, “Our collaboration aims to transform psychiatric care by developing novel neuroplastogens, promising a new era of treatment options.” Gilgamesh receives an initial $65 million from AbbVie, with potential milestones totaling $1.95 billion plus royalties. Gilgamesh CEO jonathan sporn adds, “This partnership accelerates our mission to improve mental health treatments, promising better outcomes for patients.” Discover more about this pioneering approach to mental health here: https://lnkd.in/eACHCWuF For the latest in healthcare innovation, follow World Pharmaceutical Frontiers. #PsychiatricCare #MentalHealth #HealthcareInnovation #Neuroscience #WorldPharmaceuticalFrontiers 🌍

The trial-and-error approach in mental healthcare is leaving many patients behind. While precision medicine in oncology often garners the most attention (and capital), precision psychiatry holds immense—and often overlooked—potential. With 50% of the U.S. population expected to be diagnosed with a psychiatric disorder in their lifetime, misdiagnosis rates as high as 66%, and poor efficacy of many first-line medications, the need for a more personalized approach is urgent. Leveraging neurobiology to match patients with the right treatments could revolutionize care by addressing this significant unmet need. Precision psychiatry is poised to transform the field by replacing subjectivity with science. 🚀 Companies to Watch: Alto Neuroscience: IPO'd at $147.9MM in 2024 after meeting Phase 2 primary outcomes. They demonstrated that EEG-defined biomarkers are predictive of treatment response in therapeutic candidates for Major Depressive Disorder. Circular Genomics: Raised $8.3MM in Series A funding in 2024 and recently launched its first product—a circular RNA biomarker-based assay that predicts whether patients with depression will respond to first-line medications. As precision psychiatry continues to evolve, it will be exciting to see which biomarkers emerge as the most effective for predicting treatment responses and diagnosing patients. Links below. #precisionmedicine #precisionhealthcare #precisionpsychiatry

An analysis of 15,000 de-identified Tempus nP PGx patient records, recently published in Molecular Psychiatry, revealed that 65% of patients had CYP2D6 and CYP2C19 phenotypes actionable for medication prescribing. More than half of the top 25 most frequently prescribed medications in psychiatry are metabolized by CYP2D6 and CYP2C19, emphasizing the importance of these findings. Access the full manuscript here: https://tempus.co/3VMYjZW